SPRO Stock Earnings Estimates Increased by HC Wainwright

Spero Therapeutics, Inc. (NASDAQ:SPRO – Free Report) – Equities research analysts at HC Wainwright lifted their Q4 2026 earnings estimates for Spero Therapeutics in a research note issued on Monday, November 16th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.12) per share for the quarter, up from their previous estimate of ($0.14). HC Wainwright currently has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Spero Therapeutics’ current full-year earnings is ($0.58) per share.

Spero Therapeutics (NASDAQ:SPRO – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.29). Spero Therapeutics had a return on equity of 13.98% and a net margin of 24.90%.

SPRO has been the topic of a number of other research reports. Cantor Fitzgerald began coverage on Spero Therapeutics in a research note on Wednesday, October 28th. They set an “overweight” rating and a $6.00 price target on the stock. Compass Point upgraded Spero Therapeutics to a “neutral” rating in a report on Monday, September 14th. Weiss Ratings raised Spero Therapeutics from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, November 10th. Wall Street Zen downgraded Spero Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, November 14th. Finally, Zacks Research upgraded Spero Therapeutics to a “hold” rating in a research note on Monday, September 14th. Two research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $6.00.

Get Our Latest Analysis on SPRO

Spero Therapeutics Stock Performance

SPRO stock opened at $0.87 on Wednesday. The company has a 50 day moving average price of $1.12 and a two-hundred day moving average price of $1.89. The stock has a market capitalization of $50.92 million, a P/E ratio of 11.27 and a beta of 1.59. Spero Therapeutics has a one year low of $0.87 and a one year high of $3.08.

Institutional Investors Weigh In On Spero Therapeutics

Institutional investors have recently bought and sold shares of the stock. Alphabet Inc. acquired a new stake in Spero Therapeutics during the second quarter worth about $1,967,000. BlackRock Inc. purchased a new position in shares of Spero Therapeutics in the 2nd quarter worth about $1,314,000. GSA Capital Partners LLP purchased a new position in shares of Spero Therapeutics in the 2nd quarter worth about $632,000. Marshall Wace LLP acquired a new position in shares of Spero Therapeutics in the 3rd quarter valued at about $236,000. Finally, Empowered Funds LLC acquired a new position in shares of Spero Therapeutics in the 3rd quarter valued at about $77,000. 25.60% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Spero Therapeutics

In related news, insider Esther Rajavelu sold 40,851 shares of the firm’s stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $1.04, for a total value of $42,485.04. Following the sale, the insider directly owned 946,000 shares of the company’s stock, valued at approximately $983,840. This trade represents a 4.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.90% of the stock is currently owned by insiders.

Spero Therapeutics Company Profile

(Get Free Report)

Spero Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for serious and difficult-to-treat bacterial infections. Its work has centered on antibiotic candidates intended to address infections for which existing treatment options may be limited. The company’s pipeline has included tebipenem HBr, an oral antibiotic candidate studied for complicated urinary tract infections, and programs targeting drug-resistant Gram-negative bacteria and nontuberculous mycobacterial infections.

Read More

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.